Cellares raises $257M Series D to automate cell therapy manufacturing

The cell and gene therapy boom is running into its manufacturing bill.  Traditional production remains manual and expensive, which makes the ROI for many therapies murky at best. Venture funding in the sector has plunged more than 80% from its 2021 peak. Cellares is betting the path forward is industrial. The South San Francisco company… The post Cellares raises $257M Series D to automate cell therapy manufacturing appeared first on Drug Discovery and Development.

Continue reading →